Icahn School of Medicine at Mount Sinai and ketamine research
Pioneering research on ketamine for PTSD, including some of the first randomized trials in this population.
Overview
Mount Sinai has produced some of the most influential clinical research on ketamine for post-traumatic stress disorder, including randomized controlled trials in veterans and civilians with chronic PTSD. Their program has shaped how the field thinks about rapid-acting interventions for trauma-related conditions.
Key contributions
- First RCT of intravenous ketamine for chronic PTSD
- Repeated-dose protocols for trauma-related symptoms
- Research on durability of response and relapse prevention
Selected studies
Efficacy of intravenous ketamine for chronic PTSD
Randomized controlled trial demonstrating significant reduction in PTSD symptoms 24 hours after infusion.
Visit the institution
Learn more directly from Mount Sinai at https://icahn.mssm.edu/.
Location: New York, New York, USA. Studies listed here are representative and not exhaustive. For full literature, consult PubMed or the institution's own publications.
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.